{"id":806215,"date":"2026-05-01T21:23:01","date_gmt":"2026-05-01T21:23:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=806215"},"modified":"2026-05-01T21:23:01","modified_gmt":"2026-05-01T21:23:01","slug":"interstitial-lung-disease-treatment-pipeline-shows-strong-momentum-as-120-pharma-companies-in-the-race-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/interstitial-lung-disease-treatment-pipeline-shows-strong-momentum-as-120-pharma-companies-in-the-race-delveinsight_806215.html","title":{"rendered":"Interstitial Lung Disease Treatment Pipeline Shows Strong Momentum as 120+ Pharma Companies in the Race | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/05\/1777630508.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Interstitial Lung Disease Treatment Pipeline Shows Strong Momentum as 120+ Pharma Companies in the Race | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/05\/1777630508.jpg\" alt=\"Interstitial Lung Disease Treatment Pipeline Shows Strong Momentum as 120+ Pharma Companies in the Race | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong>Interstitial Lung Diseases Pipeline Insight 2026<\/strong>&rdquo; report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Diseases pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Interstitial Lung Diseases pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Discover the latest drugs and treatment options in the Interstitial Lung Diseases Pipeline @<\/strong> <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/interstitial-lung-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Interstitial Lung Diseases Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>On April 29, 2026- Vicore Pharma AB<\/em><\/strong> initiated a ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.<\/li>\n<li><strong><em>On April 29, 2026- Avalyn Pharma Inc<\/em><\/strong>. announced a study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants will have their final dose of drug at the end of study visit from the lead-in study and first AP-LTE-008 study visit on the same day.<\/li>\n<li><strong><em>On April 29, 2026- Boehringer Ingelheim<\/em><\/strong> initiated a study for about 7.5 to 13 months depending on when they join the study. During this time, they visit the study site about 9 to 10 times. At study visits, participants have lung function tests. At select visits, chest imaging is performed. Participants fill in questionnaires about their symptoms and quality of life. The results between the 2 groups are compared to see whether the treatment works. The doctors also regularly check participants&#8217; health and take note of any unwanted effects.<\/li>\n<li><strong><em>On April 27, 2026- Calluna Pharma AS<\/em><\/strong> conducted a clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC).<\/li>\n<li><strong><em>On April 27, 2026- AllRock Bio Inc. <\/em><\/strong>announced a phase 2a study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval\/authorization.<\/li>\n<li><strong><em>On April 24, 2026- Sunshine Lake Pharma Co. Ltd<\/em><\/strong>. announced a phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing interstitial lung diseases. This study is divided into two stages, i.e. main study stage with 24 weeks treatment duration followed by up to 96 weeks treatment extended study stage.<\/li>\n<li><strong><em>On April 23, 2026- Rein Therapeutics<\/em><\/strong> initiated a research is to evaluate LTI-03 including: its safety, whether it causes side effects, whether it improves lung scarring, and whether it improves IPF symptoms. LTI-03 will be compared to placebo in patients diagnosed with IPF within the last 5 years. Patients on a stable dose of nintedanib, pirfenidone, or nerandomilast (if available by prescription) may participate.<\/li>\n<li><strong><em>On April 23, 2026- Insmed Incorporated<\/em><\/strong> conducted a study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.<\/li>\n<li><strong><em>On April 23, 2026- United Therapeutics<\/em><\/strong> conducted a phase 3 study to evaluate the safety and efficacy of inhaled treprostinil in subjects with PPF over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.<\/li>\n<li><strong><em>On April 22, 2026- Pulmovant Inc<\/em><\/strong>. announced a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.<\/li>\n<li>DelveInsight&rsquo;s Interstitial Lung Diseases Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Diseases treatment.<\/li>\n<li>The leading Interstitial Lung Diseases Companies such as <strong><em>Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences<\/em><\/strong> and others.<\/li>\n<li>Promising Interstitial Lung Diseases Pipeline Therapies such as <strong><em>Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev&reg;), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Interstitial Lung Diseases Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Interstitial Lung Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Interstitial lung disease (diffused parenchymal diseases) are a heterogeneous group of disorders characterized by fibrosis (scarring) of the lungs. These are classified on the basis of histopathological, radiologic and clinical parameters. The classification system used to describe interstitial lung disease categorizes conditions based on clinical, histopathological or radiologic parameters. Clinical classification groups ILD by its causes to help differentiate exogenous or endogenous factors. Interstitial lung disease diseases without identifiable causes get grouped under idiopathic\/primary which uses the histopathological and radiological approach as its infrastructure. Many of the subsets of the disease are of unknown etiology. Regardless, they all ultimately share the same manner of development. The morphological changes seen histologically result from a sequence of inflammation within the parenchyma, which is the portion of the lung involved in gas exchange (the alveoli, the alveolar ducts, and the bronchioles). This compartment is the habitat to various proteins and pro-fibrotic elements. These proteins, after repeated cycles of activation, give rise to accumulation of connective tissue. The trigger can be a known agent that deposited within the lung tissues. In some cases, the fibrosis arises spontaneously<\/p>\n<p style=\"text-align: justify;\"><strong>Interstitial Lung Diseases Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>DWN12088: Daewoong Pharmaceutical<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">DWN12088 is an investigational therapy for idiopathic Interstitial Lung Diseases (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body&rsquo;s ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein&rsquo;s sequence. The FDA designated it as an orphan drug for idiopathic Interstitial Lung Diseases (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>LYT-100: PureTech<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">LYT-100 is PureTech&#8217;s most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>BMS-986278: Bristol-Myers Squibb<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic Interstitial Lung Diseases. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and &beta;-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation.<\/p>\n<p style=\"text-align: justify;\"><strong>The Interstitial Lung Diseases Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Diseases with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Diseases Treatment.<\/li>\n<li>Interstitial Lung Diseases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Interstitial Lung Diseases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Diseases market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Explore groundbreaking therapies and clinical trials in the Interstitial Lung Diseases Pipeline @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">New Interstitial Lung Diseases Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Interstitial Lung Diseases Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Interstitial Lung Diseases Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Small molecule<\/li>\n<li>Cell Therapy<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Unveil the future of Interstitial Lung Diseases Treatment @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Interstitial Lung Diseases Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Interstitial Lung Diseases Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Interstitial Lung Diseases Companies- <strong><em>Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences<\/em><\/strong> and others.<\/li>\n<li>Interstitial Lung Diseases Pipeline Therapies- <strong><em>Dotarem, efzofitimod 450 mg, Fentanyl Citrate, Belimumab, Nintedanib (Ofev&reg;), Anlotinib, Pirfenidone, BI 1015550, Bosentan, Mycophenolate mofetil, Cyclophosphamide<\/em><\/strong> and others.<\/li>\n<li>Interstitial Lung Diseases Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Interstitial Lung Diseases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get the latest on Interstitial Lung Diseases Therapies and clinical trials @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/interstitial-lung-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Interstitial Lung Diseases Companies, Key Products and Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Interstitial Lung Disease: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Interstitial Lung Disease&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>RO-0220912: Roche<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Daratumumab: Janssen Biotech<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>BGB 16673: BeiGene<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Inactive Products<\/li>\n<li>Interstitial Lung Disease Key Companies<\/li>\n<li>Interstitial Lung Disease Key Products<\/li>\n<li>Interstitial Lung Disease- Unmet Needs<\/li>\n<li>Interstitial Lung Disease- Market Drivers and Barriers<\/li>\n<li>Interstitial Lung Disease- Future Perspectives and Conclusion<\/li>\n<li>Interstitial Lung Disease Analyst Views<\/li>\n<li>Interstitial Lung Disease Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=interstitial-lung-disease-treatment-pipeline-shows-strong-momentum-as-120-pharma-companies-in-the-race-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/interstitial-lung-disease-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=interstitial-lung-disease-treatment-pipeline-shows-strong-momentum-as-120-pharma-companies-in-the-race-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s &ldquo;Interstitial Lung Diseases Pipeline Insight 2026&rdquo; report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Diseases pipeline drug profiles, including clinical and nonclinical stage products. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/interstitial-lung-disease-treatment-pipeline-shows-strong-momentum-as-120-pharma-companies-in-the-race-delveinsight_806215.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-806215","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/806215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=806215"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/806215\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=806215"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=806215"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=806215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}